1-6 of 6
Wayne R Godfrey, MD
Close
Sort by
Journal Articles

Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I/II Results

Sven de Vos, MD PhD, Nina D. Wagner-Johnston, MD, Steven E. Coutre, MD, Ian Flinn, Marshall T. Schreeder, MD, Nathan Fowler, MD, Jeff P. Sharman, MD, Ralph V. Boccia, MD, Jaqueline C. Barrientos, MD, Kanti R. Rai, MD, Thomas E Boyd, MD, Richard R. Furman, MD, Leanne M. Holes, Yeonhee Kim, PhD, Wayne R. Godfrey, MD, John P. Leonard, MD
Journal: Blood
Blood (2014) 124 (21): 3063.
https://doi.org/10.1182/blood.V124.21.3063.3063
Published: 2014
Journal Articles

Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)

Ajay K. Gopal, MD, Brad S. Kahl, MD, Sven de Vos, MD PhD, Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Wojciech Jurczak, MD PhD, Ian W. Flinn, MD PhD, Christopher R. Flowers, MD, Peter Martin, MD, Andreas Viardot, MD, Kristie A. Blum, MD, Andre Goy, MD, Andrew Davies, BM PhD, Pier Luigi Zinzani, MD, Martin H. Dreyling, MD, Leanne M. Holes, Bess Sorensen, PhD, Wayne R. Godfrey, MD, Gilles Andre Salles, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1708.
https://doi.org/10.1182/blood.V124.21.1708.1708
Published: 2014
Journal Articles

Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)

Ajay Gopal, MD, Brad S. Kahl, MD, Sven De Vos, MD, PhD, Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Kristie A. Blum, MD, Wojciech J. Jurczak, Ian W. Flinn, MD, PhD, Christopher R. Flowers, MD, Peter Martin, MD, Andreas Viardot, MD, PhD, Andre Goy, MD, Andrew Davies, BM PhD, Pier Luigi Zinzani, MD, Martin H. Dreyling, MD, Leanne M. Holes, Daniel Li, PhD, Roger Dansey, MD, Wayne R. Godfrey, MD, Gilles A. Salles, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 85.
https://doi.org/10.1182/blood.V122.21.85.85
Published: 2013
Journal Articles

Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study

Nathan H Fowler, MD, Sven de Vos, MD, PhD, Marshall T. Schreeder, MD, John P. Leonard, MD, Ian W. Flinn, MD, PhD, Steve Coutre, MD, Nina D. Wagner-Johnston, MD, Jeff Sharman, MD, Ralph V. Boccia, MD, Jacqueline C. Barrientos, MD, Thomas E. Boyd, MD, Leanne M. Holes, Brian J. Lannutti, PhD, David Johnson, Thomas M. Jahn, MD/PhD, Langdon L Miller, MD, Wayne R Godfrey, MD
Journal: Blood
Blood (2012) 120 (21): 3645.
https://doi.org/10.1182/blood.V120.21.3645.3645
Published: 2012
Journal Articles

CD4 + CD25 + Regulatory T Cells from Cord Blood Have Functional and Molecular Properties of T Cell Anergy.

Lequn Li, MD, PhD, Wayne R. Godfrey, MD, Stephen B. Porter, Ying Ge, Carle H. June, MD, Bruce R. Blazar, MD, Vassiliki A. Boussiotis, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 316.
https://doi.org/10.1182/blood.V104.11.316.316
Published: 2004
Journal Articles

Cord Blood CD4+CD25+ Derived T Regulatory Cell Lines Express FoxP3 Protein and Manifest Potent Suppressor Function.

Wayne R. Godfrey, MD, Darrin J. Spoden, Ying G. Ge, Seth R. Baker, Baoling Liu, Bruce L. Levine, PhD, Carl H. June, MD, Bruce R. Blazar, MD, Stephen B. Porter
Journal: Blood
Blood (2004) 104 (11): 2124.
https://doi.org/10.1182/blood.V104.11.2124.2124
Published: 2004